Matches in SemOpenAlex for { <https://semopenalex.org/work/W2763065303> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2763065303 abstract "Ruxolitinib phosphate is an inhibitor drug of the JAK family of protein kinases. The results from two Phase III studies in myelofibrosis (COMFORT-I, COMFORT-II) demonstrate the effectiveness of Ruxolitinib in patients with primary myelofibrosis (MF), post-polycythemia vera myelofibrosis (PV-MF) and post-essential thrombocythemia myelofibrosis (ET-MF). On the other hand, Ruxolitinib affects several cytokines (IL1, IL6 and TNF-a) and other immune processes (dendritic cells function and T-cell response) and has been linked to increased incidence of opportunistic and non-opportunistic infections. The JAK-inhibitor Ruxolitinib affects the dendritic cell differentiation, phenotype, and function leading to impaired T-cell activation. Varicella zoster virus (VZV) infections are usually considered as having benign clinical courses. However, it sometimes can cause potentially fatal or long term disabling outcomes, including bacterial superinfections, coagulopathies, and central nervous system manifestations. Despite the low mortality rate in the immunocompetent patients, in immunocompromised patients primary VZV infections can become life-threatening. In the literature, VZV infections related allogeneic bone marrow transplantation had also been presented. To our knowledge, there are no reported association between VZV and myeloproliferative disorders (MPD) other than the process of bone marrow transplantation. Here we describe the first cases with cutaneous manifestations of VZV infections, who receiving Ruxolitinib therapy for MPD." @default.
- W2763065303 created "2017-10-20" @default.
- W2763065303 creator A5011861235 @default.
- W2763065303 creator A5043620809 @default.
- W2763065303 creator A5045917230 @default.
- W2763065303 creator A5048862213 @default.
- W2763065303 creator A5049257567 @default.
- W2763065303 creator A5075530381 @default.
- W2763065303 date "2017-01-01" @default.
- W2763065303 modified "2023-09-29" @default.
- W2763065303 title "Varicella Zoster Infection Associated withPharmacological JAK-STAT Inhibition viaRuxolitinib in Myeloproliferative Diseases" @default.
- W2763065303 hasPublicationYear "2017" @default.
- W2763065303 type Work @default.
- W2763065303 sameAs 2763065303 @default.
- W2763065303 citedByCount "0" @default.
- W2763065303 crossrefType "journal-article" @default.
- W2763065303 hasAuthorship W2763065303A5011861235 @default.
- W2763065303 hasAuthorship W2763065303A5043620809 @default.
- W2763065303 hasAuthorship W2763065303A5045917230 @default.
- W2763065303 hasAuthorship W2763065303A5048862213 @default.
- W2763065303 hasAuthorship W2763065303A5049257567 @default.
- W2763065303 hasAuthorship W2763065303A5075530381 @default.
- W2763065303 hasConcept C203014093 @default.
- W2763065303 hasConcept C2522874641 @default.
- W2763065303 hasConcept C2776112149 @default.
- W2763065303 hasConcept C2776159415 @default.
- W2763065303 hasConcept C2776409557 @default.
- W2763065303 hasConcept C2778837598 @default.
- W2763065303 hasConcept C2779196057 @default.
- W2763065303 hasConcept C2780007613 @default.
- W2763065303 hasConcept C2780076729 @default.
- W2763065303 hasConcept C2780452071 @default.
- W2763065303 hasConcept C2780727368 @default.
- W2763065303 hasConcept C2781057849 @default.
- W2763065303 hasConcept C2910274570 @default.
- W2763065303 hasConcept C71924100 @default.
- W2763065303 hasConceptScore W2763065303C203014093 @default.
- W2763065303 hasConceptScore W2763065303C2522874641 @default.
- W2763065303 hasConceptScore W2763065303C2776112149 @default.
- W2763065303 hasConceptScore W2763065303C2776159415 @default.
- W2763065303 hasConceptScore W2763065303C2776409557 @default.
- W2763065303 hasConceptScore W2763065303C2778837598 @default.
- W2763065303 hasConceptScore W2763065303C2779196057 @default.
- W2763065303 hasConceptScore W2763065303C2780007613 @default.
- W2763065303 hasConceptScore W2763065303C2780076729 @default.
- W2763065303 hasConceptScore W2763065303C2780452071 @default.
- W2763065303 hasConceptScore W2763065303C2780727368 @default.
- W2763065303 hasConceptScore W2763065303C2781057849 @default.
- W2763065303 hasConceptScore W2763065303C2910274570 @default.
- W2763065303 hasConceptScore W2763065303C71924100 @default.
- W2763065303 hasIssue "2" @default.
- W2763065303 hasLocation W27630653031 @default.
- W2763065303 hasOpenAccess W2763065303 @default.
- W2763065303 hasPrimaryLocation W27630653031 @default.
- W2763065303 hasRelatedWork W1966376466 @default.
- W2763065303 hasRelatedWork W1980629288 @default.
- W2763065303 hasRelatedWork W2013377223 @default.
- W2763065303 hasRelatedWork W2043993681 @default.
- W2763065303 hasRelatedWork W2045796986 @default.
- W2763065303 hasRelatedWork W2051887590 @default.
- W2763065303 hasRelatedWork W2105235256 @default.
- W2763065303 hasRelatedWork W2111872404 @default.
- W2763065303 hasRelatedWork W2126015507 @default.
- W2763065303 hasRelatedWork W2129148152 @default.
- W2763065303 hasRelatedWork W2135796126 @default.
- W2763065303 hasRelatedWork W2254184051 @default.
- W2763065303 hasRelatedWork W2341430571 @default.
- W2763065303 hasRelatedWork W2532202680 @default.
- W2763065303 hasRelatedWork W2553304123 @default.
- W2763065303 hasRelatedWork W2989415288 @default.
- W2763065303 hasRelatedWork W3022242014 @default.
- W2763065303 hasRelatedWork W3137412230 @default.
- W2763065303 hasRelatedWork W3202087538 @default.
- W2763065303 hasRelatedWork W3212119696 @default.
- W2763065303 hasVolume "1" @default.
- W2763065303 isParatext "false" @default.
- W2763065303 isRetracted "false" @default.
- W2763065303 magId "2763065303" @default.
- W2763065303 workType "article" @default.